Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Feb 18;59(4):1435–1447. doi: 10.1002/hep.26790

Figure 8. Differential impact of sorafenib on liver versus tumor-associated fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ cells in HCC.

Figure 8

The differential effects of sorafenib are the result of increased intratumoral hypoxia, leading to elevated SDF1α expression and Gr-1+ myeloid cell infiltration. Blocking CXCR4 prevents Gr-1+ myeloid cell infiltration and hepatic stellate cells differentiation and activation, and synergizes with the anti-tumor effects of sorafenib.